(Israel21c) Abigail Klein Leichman - Up to 95% of the 463 million people in the world with diabetes, have type 2 (T2D). Zygosid-50, a drug under development by Concenter BioPharma in Israel, could be the first to restore near-normal cellular sensitivity to insulin, without side effects. In animal trials, Zygosid-50 restored insulin sensitivity by better than 90%.
2020-01-31 00:00:00Full ArticleBACK Visit the Daily Alert Archive